Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children

Janet A. Englund a,*, Ruth A. Karron b, Coleen K. Cunningham c, Philip LaRusso d, Ann Melvin a, Ram Yoge v e, Ed Handelsman f, George K. Siberry g, Bhavanji Thumar b, Elizabeth Schappell h, Catherine V. Bull i, Helen Y. Chu j, Anne Schaap-Nutt k, Ursula Buchholz l, Peter L. Collins h, Alexander C. Schmidt h, the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group1

a Seattle Children’s Hospital, University of Washington, 4800 Sand Point Way NE, Seattle, WA 98105, United States
b Center for Immunization Research, Johns Hopkins University, Bloomberg School of Public Health, 624 North Broadway, Baltimore, MD 21295, United States
c Duke University Medical Center, Durham, NC, United States
d Department of Pediatrics, Columbia University, New York, NY, United States
e Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
f Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States
g Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, United States
h Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

A R T I C L E   I N F O

Article history:
Received 10 June 2013
Received in revised form 13 September 2013
Accepted 23 September 2013
Available online 5 October 2013

Keywords:
Parainfluenza
Live-attenuated vaccine
Recombinant virus vaccine
Pediatric vaccine

A B S T R A C T

Background: Human parainfluenza virus type 3 (HPIV3) is a common cause of upper and lower respiratory tract illness in infants and young children. Live-attenuated cold-adapted HPIV3 vaccines have been evaluated in infants but a suitable interval for administration of a second dose of vaccine has not been defined.

Methods: HPIV3-seronegative children between the ages of 6 and 36 months were randomized 2:1 in a blinded study to receive two doses of \(10^5\) TCID50 (50% tissue culture infectious dose) of live-attenuated, recombinant cold-passaged human PIV3 vaccine (rHPIV3cp45) or placebo 6 months apart. Serum antibody levels were assessed prior to and approximately 4–6 weeks after each dose. Vaccine virus infectivity, defined as detection of vaccine-HPIV3 in nasal wash and/or a ≥ 4-fold rise in serum antibody titer, and reactogenicity were assessed on days 3, 7, and 14 following immunization.

Results: Forty HPIV3-seronegative children (median age 13 months; range 6–35 months) were enrolled; 27 (68%) received vaccine and 13 (32%) received placebo. Infectivity was detected in 25 (96%) of 26 evaluable vaccinees following doses 1 and 9 of 26 subject (35%) following dose 2. Among those who shed virus, the median duration of viral shedding was 12 days (range 6–15 days) after dose 1 and 6 days (range 3–8 days) after dose 2, with a mean peak log10 viral titer of 3.4 PFU/mL (SD: 1.0) after dose 1 compared to 1.5 PFU/mL (SD: 0.92) after dose 2. Overall, reactogenicity was mild, with no difference in rates of fever and upper respiratory infection symptoms between vaccine and placebo groups.

Conclusion: rHPIV3cp45 was immunogenic and well-tolerated in seronegative young children. A second dose administered 6 months after the initial dose was restricted in those previously infected with vaccine virus; however, the second dose boosted antibody responses and induced antibody responses in two previously uninfected children.

© 2013 Elsevier Ltd. All rights reserved.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

* Corresponding author at: Pediatric Infectious Diseases, Seattle Children’s Hospital, 4800 Sand Point Way NE, MA 7.234, Seattle, WA 98105, United States.
Tel.: +1 206 987 6487.
E-mail address: janet.englund@seattlechildrens.org (J.A. Englund).
1 P1096 site acknowledgements are given in Appendix A.

0264-410X/$ – see front matter © 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.vaccine.2013.09.046
1. Introduction

Human parainfluenza virus type 3 (HPIV3) is an important cause of respiratory disease in infants and young children, responsible for both upper respiratory disease as well as lower respiratory tract disease including bronchiolitis and pneumonia [1,2]. Human parainfluenza viruses (HPIV) types 1–4 are associated with a substantial burden of disease in children overall, resulting in frequent medical care and hospitalization for pediatric respiratory disease [3]; HPIV3 alone is second only to respiratory syncytial virus (RSV) for causing bronchiolitis and pneumonia in infants less than 6 months of age [1]. Patients of all ages with underlying pulmonary disease or immunocompromising conditions may have serious disease related to HPIVs, with HPIV3 being the most important among these viruses [4–6]. There is currently no licensed vaccine or antiviral therapy available for the prevention or treatment of HPIV3.

Live-attenuated HPIV3 vaccines have been developed and undergone clinical testing over the past several decades [7–10]. The use of the intranasal route for administration of live-attenuated viral vaccines may offer advantages for immunization against HPIV in young children, including the potential for induction of both mucosal and systemic immunity against infection [7–9,11]. As with live-attenuated influenza virus vaccines, more than one dose of these live-attenuated vaccines may be needed to induce sustained protection in infants and young children [9,12].

Two approaches to development of live-attenuated HPIV3 vaccines have been taken. The related animal virus bovine PIV3 was used to create chimeric human bovine PIV3 vaccines [13–16]. In addition, live-attenuated vaccine candidates from human HPIV3 strains were derived via repeated passages at low temperature [17–20]. The most attenuated of these, designated cp45, was extensively evaluated in phase I and II clinical trials in children and infants as young as one month of age [8,21–23].

More recently, a cDNA-derived recombinant version of this biologically derived vaccine was developed, designated rHPIV3cp45. The rHPIV3cp45 vaccine contains the 15 known attenuating mutations present in the biologically derived virus [24]. The use of a cDNA approach has the advantage of using a virus with a short, well-characterized passage history as well as the ability to readily regenerate and modify the virus as needed [7]. The rHPIV3cp45 vaccine was recently evaluated in a phase I trial in which infants ages 6–12 months were randomized to receive two doses of rHPIV3cp45 vaccine or placebo, administered 4–10 weeks apart [25]. While the safety profile and the infectivity of the first dose of rHPIV3cp45 were similar to that previously observed with the biologically derived virus, the second dose of vaccine was highly restricted in replication and did not boost serum antibody responses [25]. For this reason, we explored whether extending the interval between doses might enhance the infectivity and immunogenicity of a second dose of vaccine. The purpose of this study was to determine the tolerability, infectivity, and immunogenicity of two 10^5 TCID₅₀ doses of rHPIV3cp45 administered 6 months apart to HPIV3 seronegative infants and children.

2. Materials and methods

2.1. Vaccine

The experimental vaccine rHPIV3cp45 is a live recombinant (r)-derived attenuated human (H) PIV3 virus that is genetically and phenotypically comparable to the extensively evaluated, biologically derived HPIV3cp45 vaccine [25], the vaccine previously evaluated in infants as young as 1–2 months of age [8]. The seed virus for the production of this experimental vaccine was generated at the Laboratory of Infectious Diseases (LID), National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) in Bethesda, MD. The clinical lot of vaccine virus was prepared at Charles River Laboratories (Malvern, PA). The rHPIV3cp45 clinical lot (Lot PIV3#102A) was tested for sterility, infectivity, sequence identity, safety in animals, and the presence of adventitious agents. The lot passed all tests satisfactorily. Vaccine virus was stored frozen at −70°C and had a mean infectivity titer of 10^7 tissue culture infectious doses (TCID₅₀) per mL. Final vial content was diluted to dose on-site.

2.2. Study population

This randomized, double-blind, placebo-controlled outpatient trial enrolled HPIV3 seronegative subjects between the ages of 6 and 36 months who were randomized in a 2:1 ratio to receive 2 doses of vaccine or placebo, respectively. The ClinicalTrials.gov identifier for this study is NCT01254175. For the purpose of this study, HPIV3-seronegative was defined as a hemagglutination inhibition (HAI) serum antibody titer of <1:8 [8,21,23]. The study was conducted between March 2010 and June 2012 at the Johns Hopkins University Center for Immunization Research (CIR), Baltimore, MD, the Seattle Children’s Research Institute (SchRI) in Seattle, WA, and the following pediatric clinical research sites affiliated with the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT): Miller Children’s Hospital, Long Beach, CA; University of California-San Diego, San Diego, CA; Rush University, Cook County Hospital, Chicago, IL; Lurie Children’s Hospital of Chicago, Chicago, IL; Columbia University Medical Center, New York, NY; Duke University Medical Center, Durham, NC; Seattle Children’s Hospital, Seattle, WA; and San Juan City Hospital, San Juan, Puerto Rico.

Inclusion criteria for young children participating in this trial included being in a good state of health, up–to–date on routine immunizations, and having parents or legal guardians willing and able to sign informed consent. Children were excluded from participation if they had known or suspected reactive airway disease, major congenital malformations, impaired immunological functions, were receiving immunosuppressive therapy or were recipients of a solid organ or bone marrow transplant, lived in a home environment with a young infant <6 month of age or a severely immunosuppressed family member, had been previously immunized with HPIV3 vaccine or were known to have hypersensitivity to any vaccine component. Children born to HIV-infected women were eligible if the child was confirmed to be HIV-uninfected. Children who had a recent fever (>100.7°F), an acute upper respiratory illness, recent acute otitis media, received a live-attenuated routine vaccine within 4 weeks or inactivated routine vaccine within 2 weeks, received systemic steroids or antibiotics, or a history of prematurity (<37 weeks gestation) with an age <1 year were deferred for later enrollment.

2.3. Study design

Children were screened for HPIV3 antibody within 30 days prior to enrollment. At enrollment, seronegative children were randomized to receive 2 doses of 10^5 TCID₅₀ of vaccine virus or placebo (1x qualified Leibovitz L-15 medium, Lonza, Walkersville, MD) approximately 6 months apart (Fig. 1). Subjects were randomized 2:1 to receive 2 doses of vaccine or 2 doses of placebo using a predetermined randomization scheme assigned by the unblinded pharmacy or laboratory dispenser. A volume of 0.5 mL of vaccine or placebo was delivered via nose drops (0.25 mL per nostril) by a blinded study nurse using a sterile, needle-less syringe while the subject was supine. Immediately after dosing, subjects remained
supine for approximately 60 s and were observed for adverse events for 30 min.

Serum was collected prior to the first dose, immediately prior to the second dose, and 4–6 weeks after the second dose. Nasal washes were performed prior to inoculation (day 0) and on days 3(+1), 7(+1), and 14(−2) following inoculation for each dose. As described below, the infectivity and phenotypic stability of the vaccine virus were assessed at each study visit from collected nasal wash specimens.

All subjects were monitored for 17 days following each inoculation for respiratory or febrile illnesses [25], with additional physical examination and nasal wash collection in the event of respiratory or febrile illness. Parents and study staff monitored temperature daily using the Phillips Sensor Touch® thermometer, a temporal artery thermometer, to screen for elevated temperatures [26]. Any temporal temperature ≥100 °F was verified by obtaining rectal temperatures within 20 min using standard thermometers provided by the study. Prior to immunization and when illness symptoms were reported, nasal washes were obtained and tested for adventitious agents by viral culture and/or rRT-PCR testing (Fast-track Diagnostics, Luxembourg). Lower respiratory tract infections (LRIs), defined as confirmed wheezing, rales, pneumonia, croup, or rhonchi, or radiologic evidence of pneumonia, were categorized as serious adverse events, regardless of severity.

2.4. Clinical trial oversight

Written informed consent was obtained from parents or legal guardians of study participants prior to screening and enrollment. These studies were conducted in accordance with the principles of the Declaration of Helsinki and the standards of Good Clinical Practice (as defined by the International Conference on Harmonization). This study was performed under the NIAID-held investigational new drug application BB-IND#12592 and was reviewed by the US Food and Drug Administration. The clinical protocols, consent forms, and investigator-brochures were developed by CIR, SCHRI, IMPAACT, and NIAID investigators, and were reviewed and approved by each institution’s respective institutional review boards as well as the NIAID Regulatory Compliance and Human Subjects Protection Branch (RCHSPB). Clinical data were regularly reviewed by clinical and NIAID investigators and by the Data Safety Monitoring Board of the NIAID Division of Clinical Research.

2.5. Isolation and quantitation of vaccine virus

Nasal washes were performed using a sterile nasal bulb syringe and 15–20 mL of lactated Ringer’s solution instilled into the child’s nares. Aliquots of nasal washes were snap frozen in sucrose-phosphate-glutamate viral transport medium as previously described [8] and stored at −80 °C. For primary virus isolation and quantitation, an aliquot of each nasal wash was rapidly thawed and inoculated onto LLC-MK2 cells and incubated at 32 °C at the CIR laboratory [8,27]. Titers of vaccine virus are expressed as tissue-culture infectious dose 50 (TCID50) per mL of nasal wash fluid, with a lower limit of detection of 10^0.0 TCID50/mL.

2.6. Genotypic characterization of vaccine virus

To differentiate between infection with rHPIV3cp45 vaccine virus and intercurrent natural infection with wild-type (wt) HPIV3, nucleotide sequencing was performed on isolates obtained at the peak of virus shedding from all children who shed HPIV3 after either dose of vaccine. Virus isolates were produced by inoculating nasal wash onto LLC-MK2 cells and harvesting the supernatant 6–7 days later. Viral RNA was extracted using QiAamp Viral RNA Mini Kits (Qiagen, Valencia, CA), and cDNA was generated using Superscript First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). For each sample, cDNA was amplified with the Clontech Advantage HF 2 PCR Kit (Clontech, Mountain View, CA) to generate a PCR product covering a segment of the F gene (nucleotides 5000–7251) that contains two attenuating mutations in rHPIV3cp45 (encoding Ile-420 to Val and Ala-450 to Thr). DNA was purified using the High Pure PCR Product Purification kit (Roche Diagnostics, Mannheim, Germany). Sequencing was performed using ABI Big-Dye (Applied Biosystems, Foster City, CA) on an ABI3730 sequencer.

2.7. Detection of adventitious viral agents

Nasal wash specimens obtained just prior to inoculation, on days 3 (range 3–4 days), 7 (range 6–8 days), and 14 (range 12–14 days), and at the time of any respiratory or febrile illness were tested for adventitious viral agents either by viral culture [8,27] or by reverse transcription real-time polymerase chain reaction assay (rRT-PCR; Fast-track Diagnostics, Luxembourg). Tested adventitious agents included the following: coronavirus, adenovirus,
enterovirus, parechovirus, respiratory syncytial virus A/B, parainfluenza viruses types 1–4, human metapneumovirus A/B, bocaviruses, and mycoplasma pneumoniae.

2.8. Antibody assays

Serum specimens were stored frozen until use. Sera were tested for HPIV3 antibody by the HAI antibody test method, starting at a serum dilution to 1:4, with 2-fold dilution increments and endpoint titration [25].

2.9. Data analysis

Infection with vaccine virus was defined as either the isolation of vaccine virus or a ≥ 4-fold rise in antibody titer [25]. The mean peak titer of vaccine virus shed (log$_{10}$ TCID$_{50}$/mL) and duration (last day) of shedding were calculated for infected vaccinees only. Data were analyzed using Stata 12.0 (STATA Corp, College Station, TX). HAI reciprocal titers were transformed to log$_{2}$ values for calculation of mean log$_{2}$ titers, and Student’s t-test was used to compare HAI titers between groups. Baseline data and illness rates between the groups were compared using independent sample unequal variance t-tests for continuous variables and Fisher’s exact tests for categorical variables.

3. Results

3.1. Population

A total of 40 infants and young children were enrolled into this study (Fig. 2), with a median age of 13 months (range 6–35 months). The 27 (68%) subjects randomized to receive vaccine received the first dose at a median age of 13 months (range 6–35 months), and 26 (67%) received the second dose at a median age of 18 months (range 12–40 months). The 13 placebo recipients received the first and second doses at a median age of 16 months (range 6–29 months) and 23 months (range 13–34 months), respectively. There were no significant differences in age at vaccination, gender, racial, and ethnic profiles between vaccine and placebo groups (Table 1). Thirty-nine (98%) subjects received two doses of vaccine (n = 26) or placebo (n = 13). Thirty-nine (98%) had a blood sample obtained following the first dose and second dose vaccine. The median duration of participation for each subject was 28 weeks (range 26–32 weeks). Study follow-up was excellent, with only one subject lost to follow-up.

3.2. Vaccine safety and reactogenicity

The rHPIV3cp45 vaccine was well tolerated by the study subjects. No serious adverse events related to study vaccine were reported in any subject; specifically, no lower respiratory tract disease or other respiratory illnesses requiring medical attention considered to be related to study vaccine occurred throughout the trial. Rates of fever did not differ significantly between vaccine and placebo groups following either dose 1 or dose 2 of study drug, with rates similar and < 1% in both vaccine and placebo groups following each vaccine dose (Table 2). Mild upper respiratory signs and symptoms were common following both dose 1 and 2 of vaccine and placebo (Table 2), but cough was uncommon, occurring only in 3 (11%) vaccine recipients after the first dose of vaccine. Otitis media was documented following the first dose of study drug in one (4%) vaccine recipient (first documented on day 15) and one (8%) placebo recipient (first documented on day 18). Rates of illness did not differ significantly following the first or second dose of vaccine and were similar in vaccine and placebo recipients (P = 0.73 and 0.71, respectively for dose 1 and dose 2).

Nasal washes obtained from participants were tested for adventitious agents on day 9 prior to vaccination with study drug. Nasal washes were also obtained and tested for potential adventitious agents in 15 symptomatic subjects (11 vaccine recipients; 4 placebo recipients) following dose 1 and in 12 symptomatic subjects (9 vaccine recipients; 3 placebo recipients) following dose 2 (Table 2). Viruses other than rHPIV3cp45 were detected in 14/27 (52%) vaccine recipients following dose 1 of vaccine and 7/26 (27%) following dose 2. Viruses other than rHPIV3 were detected in 5/13 (38%) placebo recipients after both dose 1 and dose 2. Viruses other than rHPIV3cp45 were identified in 25 nasal wash specimens following dose 1, and 17 nasal wash specimens following dose 2. The most common adventitious agent detected throughout the study was rhinovirus: 7/40 (17.5%) with dose 1 and 6/39 (15.4%) with dose 2. Noted adventitious agents detected in both vaccinees and placebo recipients throughout the study included adenoviruses, bocaviruses, coronaviruses, enteroviruses, HPIV1 and 4, and rhinoviruses.

3.3. Infectivity and Immunogenicity of rHPIV3cp45

Shedding of vaccine virus was documented in 24 of 27 (89%) children following the first dose of vaccine and 9 of 26 (35%) following the second dose (P < 0.001) (Table 2). The median duration of viral shedding in those infected with vaccine virus was 12 days (range 6–15 days) following the first dose compared with 6 days (range 3–8 days) following the second dose of vaccine, with the peak mean log$_{10}$ titer following the first dose of 3.4 PFU/mL (SD 1.0) compared to 1.5 PFU/mL (SD 0.92) following the second dose (P = 0.001). A 4-fold or greater increase in serum antibody was documented in 23 of 26 (88%) evaluable children following the first dose of vaccine, with a mean log$_{2}$ HAI antibody titer of 5.3 ± 1.8, and in six of 26 (23%) children following the second dose, with a mean log$_{2}$ antibody titer of 6.2 ± 1.5. At the time of the first dose of vaccine, the age of vaccine recipients who were infected after dose 1 [13.9 months (SD: 1.53)] was significantly older than those who were infected after dose 2 [9.1 months (SD: 0.61)] (P = 0.007). Among vaccine recipients (n = 26), those with higher pre-dose antibody titers were less likely to shed virus (P = 0.03). The mean pre-dose 2 antibody titer in those who did not shed virus (n = 17) was 6.1 (SD 1.6), as compared to the mean pre-dose 2 antibody titer in those who did shed virus (n = 9; mean viral antibody titer 4.3 (SD 2.1)].

HPIV3 was detected in one placebo recipient beginning on day 0 of the study, prior to vaccination. This isolate was confirmed by RT-PCR amplification and sequence analysis to be wild type HPIV3 and not vaccine virus. In addition, vaccine virus was isolated from nasal wash samples of each vaccinee that shed (n = 33; 24 after does 1, 9 after dose 2) and confirmed to be vaccine virus by RT-PCR and sequencing. Isolates from all of the vaccinees contained the expected rHPIV3cp45 mutations (data not shown), thus confirming that the virus was vaccine derived, and that the attenuating mutations were maintained during vaccine virus replication.

Table 1

| Demographic characteristics of infants and children enrolled in the study. |
|---------------------------------|
| Median age, months (range)      |
| Vaccine (n = 27)                 |
| Placebo (n = 13)                 |
| P-value                         |
| Dose 1 (n = 40)                 |
| 13 (6–35)                       |
| 16 (6–29)                       |
| 0.34                            |
| Dose 2 (n = 39)                 |
| 18 (12–40)                      |
| 23 (13–34)                      |
| 0.27                            |
| Male, no (%)                    |
| 17 (63)                         |
| 7 (54)                          |
| 0.73                            |
| Race, no (%)                    |
| Asian                           |
| 0 (0)                           |
| 1 (8)                           |
| 0.33                            |
| Black                           |
| 9 (32)                          |
| 3 (23)                          |
| 0.72                            |
| Caucasian                       |
| 14 (50)                         |
| 9 (69)                          |
| 0.33                            |
| Multi-racial/unknown            |
| 4 (14)                          |
| 0 (0)                           |
| 0.28                            |
| Hispanic, no (%)                |
| 9 (33%)                         |
| 2 (15%)                         |
| 0.29                            |
Table 2

Clinical and virologic responses of infants and children following rHPIV3cp45 or placebo.

|                      | Dose 1     | P-value | Dose 2     | P-value |
|----------------------|------------|---------|------------|---------|
|                      | Vaccine    | Placebo | Vaccine    | Placebo |
| Total subjects (N)   | 27         | 13      | 26         | 13      |
| Subjects with sera collected (N) | 26         | 13      | 26         | 13      |
| N (%) of evaluable infected
dose virus shedding | 25/26 (96) | 3/13 (23) | <0.001 | 9/26 (35) | 0 (0) | 0.018 |
| N (%) of evaluable shedding vaccine virus | 24/27 (89) | 0/13 (8) | <0.001 | 9/26 (35) | 0 (0) | 0.018 |
| Median days of shedding (range) | 12 (6–15) | N/A | – | 6 (3–8) | N/A | – |
| Mean peak viral titer in log_{10} TCID_{50}/mL (SD) | 3.4 (1.0) | – | – | 1.5 (0.92) | – | – |
| N (%) of subjects with sera with 4-fold rise in antibody titer | 23 (88) | 3 (23) | <0.001 | 6 (23) | 0 (0) | 0.001 |
| Median log_{10} fold change in HAI antibody titer (range) | 5 (0–7) | 0 (0–6) | <0.001 | 0 (0–1 to 5) | 0 (0–0) | 0.017 |
| N patients with illness (%) |                      |         |                      |         |
| Fever                | 3 (11)     | 2 (15)  | 1.00     | 3 (12) | 1 (8) | 1.00 |
| Upper respiratory tract infection | 9 (33) | 4 (31) | 1.00 | 7 (27) | 2 (15) | 0.689 |
| Rhinorrhea           | 9 (33)     | 4 (31)  | 1.00     | 7 (27) | 2 (15) | 0.69 |
| Pharyngitis          | 0 (0)      | 1 (8)   | 0.33     | 0 (0) | 0 (0) | – |
| Lower respiratory tract infection | 0 (0) | 0 (0) | – | 0 (0) | 0 (0) | – |
| Cough                | 3 (11)     | 0 (0)   | 0.538    | 0 (0) | 0 (0) | – |
| Otitis media         | 1 (4)      | 1 (8)   | 1.00     | 0 (0) | 0 (0) | – |
| Any respiratory or febrile illness | 11 (41) | 4 (31) | 0.730 | 9 (35) | 3 (23) | 0.714 |

* Infection was defined as vaccine virus isolation and/or ≥4-fold rise in serum antibody titer.
* Duration of shedding was calculated for infected subjects only, and was defined as the time between inoculation and the last day on which vaccine virus was recovered.
* Mean peak titer of virus shed was calculated for infected subjects only.
Antibody responses following each vaccine dose are shown in Fig. 3. The majority of study participants (23/26, 88%) had a 4-fold or greater antibody rise following the first dose of vaccine. No subject had a 4-fold rise in titers to indicate natural infection between dose 1 and dose 2. While the mean \( \log_2 \) antibody titer did not increase significantly for the entire group of vaccinees after the second vaccine dose, \( \geq 4 \)-fold increases in titer were observed for 4 of the 5 children who had a \( \log_2 \) antibody titer of \( \leq 4 \) following the first dose of vaccine. Thus, the net effect of the second dose was to increase the proportion of subjects achieving relatively high HAI antibody titers: whereas only 15 children achieved post–vaccination \( \log_2 \) titers >6 observed following the first dose of vaccine, 21 achieved \( \log_2 \) titers >6 following the second dose. Only one evaluable vaccine recipient had neither seroconversion nor viral shedding documented. Overall infectivity, defined as either viral shedding or a \( \geq 4 \)-fold rise in antibody titer, was observed in 25 of 27 (93%) of vaccinated children following the first dose and 26 of 26 (100%) following the second dose of vaccine. Three (23%) placebo recipients had a \( \geq 4 \)-fold rise in HAI antibody titers four to six weeks following the first dose of vaccine, including the child who shed wt HPIV3.

4. Discussion

The purpose of this study was to determine whether increasing the interval between doses was able to enhance the infectivity of a second dose of rHPIV3cp45. The results of this study confirmed our initial experience with rHPIV3cp45 [25]: the vaccine was safe and well-tolerated with good rates of infectivity and antibody response following a single dose of vaccine. We demonstrated that children with a substantial antibody response following the first dose of vaccine did not seem able to be either infected or boosted when a second dose was administered approximately 6 months after the first dose. In contrast, the second dose of vaccine given six months later appeared to boost antibody titers in those with a suboptimal response following the first dose, and it was associated with lower amounts of detectable virus in the nasal wash. Of interest, children who required a second dose of vaccine to achieve an antibody response were significantly younger than those who did not. Overall, this study demonstrated that two doses separated by 6 months are able to infect children under three years of age who were not infected with a single dose of vaccine.

As expected for a pediatric trial, high rates of infections and symptoms with other viruses were common, but rates and types of viruses and symptoms were similar between placebo and vaccine groups, emphasizing the need for placebo-controlled trials. The detection of adventitious agents using molecular diagnostic techniques was helpful in assessing potential causality of fever in subjects in this trial, since many of both placebo and vaccine recipients had fever associated with infection with other viruses during the trial. Since HPIV3 typically circulates during the spring and summer months when these trials are conducted, sequence analysis proved a useful tool for differentiating between infection with wt and vaccine virus. This technology is important in assessing the safety and reactogenicity of vaccines and the conduct of clinical trials: illness in a placebo recipient was able to be directly related to infection with wtHPIV3 and not to potential spread of vaccine virus in the clinic setting.

Previous clinical studies with similar HPIV 3 vaccines have shown good immunogenicity. For example, the 2003 study by Karron et al. in adults, children, and infants revealed 82–100% infectivity of a single dose in seronegative children between the ages of 6–36 months using a dose of either \( 10^4 \) or \( 10^5 \) [8]. A later study by Bernstein et al. studied the recombinant HPIV3 vaccine utilized in our clinical trial, rHPIV3cp45, in infants 6 to less than 12 months of age with 3 doses of vaccine at a dose of \( 10^5 \) [10]. In this younger population, viral shedding after dose 1 was documented in 85% of recipients compared with 89% in our older population. After 3 doses in the Bernstein trial, either seroresponse or shedding occurred in 95% of vaccine recipients compared with our rate of infectivity (seroresponse or shedding) in 96% after dose 1 and 93% after dose 2.

Future use of this vaccine may include immunization of young infants, potentially with repeated dosing to ensure optimal immunogenicity. Since the youngest children are at highest risk for hospitalization or receiving medical care, this group would be the natural targets for immunization to provide the most protection against disease. In addition, use of rHPIV3cp45 in combination with live-attenuated RSV and human metapneumovirus (HMPV) vaccines can be envisioned as a strategy to provide broad protection against important respiratory viral pathogens of infancy and early childhood [18]. A dosing schedule for this type of vaccine would need to be harmonized with current pediatric vaccination schedules.

Acknowledgements

The study team gratefully acknowledges the contributions of families participating in this study, as well as supporting physicians, nurses, and research staff at Seattle Children’s Clinical Research Center, North Seattle Pediatrics, and Woodinville Pediatrics.

The team wishes to thank the Division of Clinical Research, especially the RCHSPB members, and the Division of AIDS, both NIAID, for their support and oversight of the study. Sonia Surman, LID/NIAID, was responsible for characterization and sequencing of virus isolates.

Financial support: This study was funded by the Intramural Research program of the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Clinical trials were conducted as part of contracts between NIAID and the Johns Hopkins Bloomberg School of Public Health (HSN272200900101C). In Seattle, this project was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1RR025014. Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632], the Eunice Kennedy Shriver National Institute of Child Health and Human Development
Agreement Children’s [NICHD], 5712 Hospital, Nicolas MD, Juan CRS Durham, en Chicago Diseases, National Allergy Frontier 1984;150(6):851–7. Elizabeth (Gina Duke Children’s Seattle, CRS, of Seattle, Shriver and WP, RM, Silva, Translational 1986;18(2): 131–7. Sato, MD, CRS, and Lum, Joanne, RN; 1986;5(4):515–20. Bernstein DS, Fallon J, Yi T, A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza type 3 vaccine in healthy infants. Vaccine 2011;29(40):7042–8. Durbin AP, RA, Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis 2003;37(12):1668–77. Lamb, K., and Reimold, A. J. Pediatr 1987;111(6): 1116–22. Schmidt AC, Schaap–Nutt A, Bartlett EJ, Schomaker H, Boonyaratankorn J, Karron RA, et al. Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med 2011;5(4):515–20. (NICHD), and the National Institute of Mental Health [NIMH] [A068632]. This work was supported by the Statistical and Data Analysis Center at Harvard School of Public Health, under the National Institute of Allergy and Infectious Diseases cooperative agreement # 1 U01 A068616 with the IMPAACT Group. Support of the sites was provided by the National Institute of Allergy and Infectious Diseases (NIAID) and the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network funded by NICHD (contract number N01-DK-9-001/HHSN267200800001C). Conflict of interest: No conflicts of interests or financial disclosures are reported by any authors. A. Schmidt is currently an employee of GlaxoSmithKline.

Appendix A. P1096 site acknowledgements

Members of the P1096 Protocol Team include: Janet A. Englund, MD, Seattle Children’s Hospital, Seattle, WA; Ruth A. Karron, MD, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Coleen K. Cunningham, MD, Duke University Medical Center, Durham, NC; Phillip LaRuska, MD, Columbia University IMPAACT CRS, New York, NY; Ann J. Melvin, MD, MPH, Seattle Children’s Hospital CRS, Seattle, WA; II, Ed Handelman, MD, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD; Peter L. Collins, PhD, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Alexander C. Schmidt, MD, PhD, Laboratory of Infectious Diseases National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Linda Marillo, BA, Frontier Science and Technology Research Foundation, Buffalo, NY; Elizabeth Petzold, PhD, Social and Scientific Systems, Silver Spring, MD; Paul Sato, MD, MPH, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD; George K. Siberry, MD, MPH, Pediatric Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Development, Bethesda, MD; Jocelynn Thomas, BSN, RN, Seattle Children’s Hospital, Seattle, WA; Joan Dragovan, M.I.M., University of Washington, Seattle, WA 98104.

Participating sites and site personnel include: 4001 Chicago Children’s CRS (Pam Sroka, BSN; Laura Fern, RN; Lynn Heald, PNP; Laurie Strotman, APN); 4601 UCSD IMPAACT CTU (Rolando Viani, MD, MTP; Stephen A Spector, MD; Jeane M Manning, RN, BSN; Anita Darcey, RN); 5083 Rush University Cook County Hospital Chicago NICHD CRS (Latania Logan, MD; Mariam Aziz, MD; Mau- reen McNichols, RN, MSN, CCRC; James Mcauley, MD, MPH); 5017 Seattle Children’s Hospital CRS (Lisa Frenkel, MD; Corry Venema- Weiss, ARNP; Jocelynn Thomas, RN; Jenna Lane ARNP; National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000423); 5031 San Juan City Hospital PR NICHD CRS (Midneta Acevedo–Flores, MD; Nicolas Rosario, MD, PD MSc; Lourdes Angeli–Nieves, RN, MPH; Dalla Guzmán–Lluberes, RPh); 4101 Columbia University IMPAACT CRS (Gina Silva, RN; Seydi Vazquez, RN; Andrea Jurguer, CNP); 4701 Duke Pediatric Infectious Diseases (John Sweanam, MEd; Mary Jo Hassett, RN; Joan Wilson, RN; Julia Giner, RN); 5093 Miller Children’s Hospital Long Beach CA. Research personnel at Seattle Children’s Hospital included Diane Kinnunen, BSN, Kirsten Lacombe, BSN, and Catherine Bull, ARNP.

References

[1] Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3: season- aility and risk of infection and reinfection in young children. J Infect Dis 1984;150(6):851–7.
[2] Chanock RM, Murphy BR, Collins PL. Parainfluenza viruses. In: Knipe DM, How- ley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al., editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1341–79.
[3] Weinberg CA, Hall CB, Iwane MK, Poehling KA, Edwards KM, Griffin MR, et al. Parainfluenza virus infections of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009;154(5):694–9.
[4] Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respira- tory virus infections on persons with chronic underlying conditions. JAMA 2002;283(4):499–505.
[5] Peck AJ, Englund JA, Kuyper J, Guthrie KA, Corey L, Morrow R, et al. Respiratory virus infections among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007;110(5):1681–8.
[6] Weinberg A, Lyu DM, Li S, Marquese J, Zamora MR. Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010;12(4):330–5.
[7] Schmidt AC, Progress in respiratory virus development. Semin Respir Crit Care Med 2011;32(4):527–40.
[8] Karron RA, Belshe BR, Wright PF, Thumar B, Burns B, Newman F, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2006;25(12):1093–9.